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Abstract
Serotonin, a biologically active amine, is related to carcinoid 
syndrome in functioning neuroendocrine tumors (NETs). 
Telotristat ethyl is a novel inhibitor of the tryptophan hy-
droxylase (TPH), a key enzyme in the production of sero-
tonin. While its use in patients with carcinoid syndrome and 
uncontrolled diarrhea under somatostatin analogs (SSAs) 
has been recently approved, in vitro data evaluating its ef-
fectiveness are lacking. For this reason, we aimed to evaluate 
the effect of telotristat as monotherapy, and in combination 
with SSAs, on proliferation and secretion in a NET cell line 
model. The human pancreatic NET cell lines BON-1/QGP-1 
were used as 2D and 3D cultured models; somatostatin re-
ceptor and TPH mRNA expression, as well as the potential 
autocrine effect of serotonin on tumor cell proliferation us-
ing a 3D culture system were evaluated. Telotristat de-
creased serotonin production in a dose-dependent manner 
at a clinically feasible concentration, without affecting cell 
proliferation. Its combination with pasireotide, but not with 
octreotide, had an additive inhibitory effect on serotonin se-
cretion. The effect of telotristat was slightly less potent, 
when BON-1 cells were co-treated with octreotide. Octreo-
tide and pasireotide had no effect on the expression of TPH. 
Telotristat did not have an effect on mRNA expression of so-
matostatin receptor subtypes. Finally, we showed that sero-
tonin did not have an autocrine effect on NET cell prolifera-
tion on the 3D cell model. These results suggest that telotri-
stat is an effective drug for serotonin inhibition, but the 
effectiveness of its combination with SST2 (somatostatin re-
ceptor subtype 2)-preferring SSA should be evaluated in 
more detail. © 2019 S. Karger AG, Basel
Introduction
Neuroendocrine tumors (NETs) are slow-growing 
neoplasms derived from neoplastic proliferation of en-
terochromaffin cells, which are able to synthesize, store, 
and secrete different types of biologically active amines 
and peptides, including serotonin [1, 2]. Serotonin is syn-
thesized from the essential amino acid l-tryptophan. 
Tryptophan hydroxylase (TPH) converts tryptophan to 
5-hydroxytryptophan, which is subsequently converted to 
serotonin [3]. Usually, serotonin, produced by a midgut 
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NET, is metabolized by the liver and does not cause sys-
temic symptoms, but when liver metastases are present, 
many patients present with systemic features of the carci-
noid syndrome, including flushing (94%), diarrhea (78%), 
abdominal pain (51%), and cardiac valvular complica-
tions (53%), which can lead to heart failure [4, 5]. Carci-
noid syndrome is usually related to metastasized midgut 
NETs, but it may also be observed in patients with bron-
chial or ovary carcinoids, even if liver metastasis is absent 
[6]. Systemic levels of serotonin can be measured by track-
ing the excretion of urinary serotonin metabolite 5-hy-
droxyindoleacetic acid (u5-HIAA). When elevated u5-
HIAA excretion is observed, the tumor is usually widely 
spread and associated with severe carcinoid syndrome 
and on the long-term carcinoid heart disease [7, 8].
Somatostatin analogs (SSAs), targeting somatostatin 
receptor (SST) subtype 2, are recognized as the standard 
of care for patients with carcinoid syndrome as SSAs in-
hibit serotonin secretion by NETs [9, 10]. Long-acting 
preparations of SSAs are especially used, since they im-
prove flushes in 53–75% and diarrhea in 45–80% of cases 
[9]. Despite the effectiveness of SSAs, loss of response 
during prolonged treatment has been reported. Tachy-
phylaxis, downregulation of cell surface SSTs, develop-
ment of antibodies to SSAs, as well as SSTs gene muta-
tions have been hypothesized [11, 12].
Telotristat ethyl is a novel TPH inhibitor. This drug 
acts peripherally due to its elevated molecular weight and 
acidic moieties, which prevent it from crossing the blood-
brain barrier, thus avoiding the inhibition of TPH in the 
central nervous system [8, 13, 14]. Its metabolite, the hip-
purate salt of telotristat ethyl, reduced serotonin levels 
throughout the gastrointestinal tract in mice and im-
proved clinical symptoms without several adverse effects 
[14]. Additionally, international, multicenter, blind, clin-
ical studies have reported significant reduction in the fre-
quency of bowel movements and urinary u5-HIAA ex-
cretion in patients with carcinoid syndrome not ade-
quately controlled by SSAs [8, 14, 15]. Telotristat ethyl 
has recently been approved by the US Food and the Drug 
Administration and the European Medicine Agency for 
the treatment of diarrhea in those patients with carcinoid 
syndrome who are inadequately controlled by SSAs. Tel-
otristat is also considered as a category 2A recommenda-
tion in the National Comprehensive Cancer Network 
clinical practice guidelines [16–18]. Despite the promis-
ing results reported in clinical trials, surprisingly very lit-
tle information on the in vitro effects of the drug is avail-
able in the literature. In this context, we aimed to evaluate 
the in vitro effect of telotristat as monotherapy, as well as 
in combination with SSAs, on proliferation and secretion 
in cell line models of NET. To the best of our knowledge, 
this study extensively describes for the first time the direct 
effects of telotristat in two-dimensional (2D) and three-
dimensional (3D) cell culture models of NETs.
Materials and Methods
Cell Cultures
The human pancreatic NET cell lines BON-1 and QGP-1 were 
used. The BON-1 cell line (kind gift of Dr. Townsend from the Uni-
versity of Texas Medical Branch, Galveston, TX, USA) was derived 
from a lymph node metastasis of a human functioning PNET. The 
cell line QGP-1 was established from a somatostatin-secreting pan-
creatic islet cell carcinoma and purchased from the Japanese Collec-
tion of Research Bioresources Cell Bank (JRCB, Osaka, Japan) [19]. 
BON-1 cells were cultured in D-MEM/F12 (GIBCO Biocult 
Europe, Breda, The Netherlands) containing 10% fetal calf serum 
(FCS), L-glutamine, fungizone (0.5 mg/L) and penicillin 105 U/L 
(Bristol-Myers Squibb, Woerden, The Netherlands). QGP-1 cells 
were cultured in RPMI 1640 (GIBCO Biocult Europe) containing 
10% FCS and penicillin 105 U/L (Bristol-Myers Squibb). Cell lines 
were cultured in 75 cm2 flasks (Greiner bio-one, The Netherlands) 
at 37 ° C in a 5% CO2 incubator. Cells were harvested with trypsin 
(0.05%)-EDTA (0.53 mM) and resuspended in culture medium. 
Cell viability always exceeded 87%. For the serotonin assays, cells 
were cultured in medium containing 0.1% bovine serum albumin 
(BSA), after an initial incubation of 24 h in medium with 10% FCS 
to allow cell attachment. 
Pancreatic NETs may produce carcinoid syndrome due to the 
secretion of serotonin and tachykinins [20–22]; the serotonin se-
cretion of BON-1 and QGP-1 cell lines has been reported in sev-
eral articles, and their neuroendocrine phenotype has recently 
been confirmed [23–25]. For these reasons, a PNET model was 
chosen for this research.
2D Cultures (Monolayer)
Cells were plated in 24-well plates with 1 mL medium at the 
density necessary to obtain a 65–70% cell confluence in the control 
groups at the end of the experiment (50,000 cells/well for BON-1 
and 30,000 cells/well for QGP-1; data not shown). Drug treatment 
was started after 24 h of incubation. In those experiments per-
formed in 0.1% BSA, a higher number of cells was used (85,000 
cells/well for BON-1 and 100,000 cells/well for QGP-1). Cells were 
incubated during 3 days with the indicated drugs. Prolonged peri-
ods of incubation in serum-deprived monolayer cultures resulted 
in a significant loss of cell viability.
3D Cultures (Spheroids)
Non-scaffold-based 3D cell cultures were used. Cells (750 cells/
well for BON-1 and 1,500 cells/well for QGP-1) were plated in cell 
repellent-coated 24-well plates (cellstar®; Greiner Bio-One B.V., Al-
phen aan den Rijn, The Netherlands). After 72 h of initial incubation 
in 1 mL medium with 10% FCS, spheroids were washed twice with 
medium containing 0.1% BSA. Medium was refreshed and drugs 
were added. Spheroids were incubated during 7 days with the indi-
cated drugs, and medium and drugs were refreshed on day 3.
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Drugs and Reagents
The active metabolite of telotristat ethyl (LP-778902, herein 
named as telotristat) was purchased from Bio-Connect B.V. (The 
Netherlands). All the experiments described in this article were 
performed with the active compound LP-778902, and its use is re-
ferred in the results as telotristat. LP-778902 was evaluated since it 
is the systemically available active compound in humans. Pasire-
otide (PAS) and octreotide (OCT) were obtained from Novartis 
Pharma (Basel, Switzerland). Telotristat was dissolved in dimethyl 
sulfoxide (DMSO). The evaluated concentrations of telotristat 
(LP-778902: 10–5 to 10–12 M) were chosen on the basis of literature 
reports and included the clinically relevant plasma concentration 
(10–8 M), which is based on the active moiety of the drug [14]. Ve-
hicle (DMSO 0.4% final concentration) was added into the control 
wells. The calculated half maximal inhibitory concentration (IC50) 
for both cells lines was used for the combination experiments with 
SSAs. The IC50 and the maximal evaluated concentration were 
used for evaluating the autocrine effect of serotonin on cell prolif-
eration in the 3D model with spheroids. PAS and OCT were dis-
solved in medium until obtaining the final concentrations tested, 
10–8 to 10–9 M, corresponding to the clinically relevant concentra-
tions according to the literature [26–28]. PAS and OCT were cho-
sen based on their different SSTs affinity (OCT and lanreotide bind 
preferably to SST2, and PAS has high binding affinity to multiple 
SSTs, particularly SST5) [29].
Measurement of Total DNA Content
After the incubation period, cells and spheroids were harvested 
for DNA measurement, as a measure of cell number. The proce-
dure for the total DNA measurement has been previously de-
scribed in detail [30, 31]. Briefly, cell pellet was treated with 150 µL 
of ammonia solution (1 mol/L) – Triton X 100 (0.2% v/v). After 15 
min, sonification was performed (Soniprep 150; amplitude 1,400 
μm). Thereafter, in 2D cultures, 1 mL assay buffer (100 mM NaCl, 
100 mM EDTA, 10 mM Tris; pH 7.0) was added, and 20 µL of the 
solution was mixed with 200 µL of Hoechst dye H33258 solution 
(1 µg/mL); fluorescence was measured with the excitation and 
emission wavelengths set at 350–455 nM and referenced to a stan-
dard curve of calf thymus DNA (type II, no D-3636; Sigma-Al-
drich, Zwijndrecht, The Netherlands). In 3D cultures (spheroids), 
the Quant-iTTM PicoGreenTM dsDNA assay kit (Thermo Fisher Sci-
entific, The Netherlands) was used, fluorescence was measured 
with the excitation and emission wavelengths set at 485–535 nM 
and referenced to the standard curve of the kit. This assay (as al-
most all the other available DNA content assays) is an indirect 
measure of DNA content. Its use was chosen based on its high ac-
curacy in fresh, homogeneous samples. Additionally, the absence 
of washing procedures (as in trypan blue assays) decreases the pos-
sibility of harvesting cells during the incubation period. Finally, no 
methods for the appropriate discrimination of all types of dead 
cells (including flow cytometric) are available, for these reasons 
[32].
Methylthiazolyldiphenyl-Tetrazolium Bromide Assay
Proliferation was confirmed by the methylthiazolyldiphenyl-
tetrazolium bromide (MTT) assay (Sigma-Aldrich). Briefly, 3,000 
cells/well were plated in 96-well plates, and on the day of measure-
ment, 100 μL of MTT diluted in d-PBS (Sigma-Aldrich) were add-
ed to the cells and then incubated for 3 h at 37  ° C. Subsequently, 
cells were detached with lysis buffer (10% SDS, 0.56% glacial acetic 
acid in DMSO) and absorbance measured using the FlexStation 
system plate reader, at 570 nm. In all instances, cells were plated 
per quadruplicate, and all assays were repeated twice. 
Quantitative RT-PCR
The mRNA expression of SSTs (SST1, SST2, SST3, SST5) in 
monolayer and spheroids in both cell lines was evaluated by quan-
titative RT-PCR. We used a previously described method [33]. In 
short, poly(A+) mRNA was isolated using Dynabeads Oligo (de-
oxythymidine)25 (Dynal AS, Oslo, Norway). The poly(A+) mRNA 
was eluted in H2O (65  ° C) twice for 2 min each and used for cDNA 
synthesis in a Tris buffer (50 mm Tris-HCl [pH 8.3], 100 mm KCl, 
4 mm dithiothreitol, and 10 mm MgCl2) with 10 U ribonuclease in-
hibitor, 2 U avian myeloblastosis virus super reverse transcriptase, 
and 1 mm of each deoxynucleotide triphosphate in a final volume 
of 40 μL. This mixture was incubated for 1 h at 42  ° C, and the result-
ing cDNA was diluted 5-fold in 160 μL sterile H2O. The total reac-
tion volume (25 μL) consisted of 10 μL cDNA and 15 μL TaqMan 
Universal PCR Mastermix (Applied Biosystems, Branchburg, NJ, 
USA). Primers were used at a final concentration of 300 nm and 
probe at 200 nm. Real-time qPCR was performed in 96-well optical 
plates with the TaqMan Gold nuclease assay (Applied Biosystems, 
Roche) and the ABI Prism 7700 Sequence Detection System (Per-
kinElmer, Foster City, CA, USA). After two initial heating steps at 
50  ° C (2 min) and 95  ° C (10 min), samples were subjected to 40 
cycles of denaturation at 95  ° C (15 s) and annealing at 60  ° C (60 s). 
All samples were assayed in duplicate. Values were normalized 
against the expression of the housekeeping gene HPRT. Dilution 
curves were constructed to calculate PCR efficiencies (E) for every 
primer-probe set [34]. To exclude genomic DNA contamination in 
the RNA, the cDNA reactions were also performed without reverse 
transcriptase and amplified with each primer pair. To exclude con-
tamination of the PCR mixtures, the reactions were also performed 
in the absence of cDNA template. The sequence of used SSTs prim-
ers and efficiencies are described in online supplementary Table 1 
(see www.karger.com/doi/10.1159/000502200 for all online suppl. 
material, ). Tryptophan hydroxylase-1 (TPH-1) PCR primers (Sig-
ma Aldrich) were designed using the Universal Probe Library of 
Roche (https://www.roche-applied-science.com) based on the re-
ported mRNA sequences in the National Center for Biotechnology 
Information database (NCBI, Bethesda, MD, USA). The primers 
and their sequences are forward TGAGACACAGTTCAGA-
TCCCTTC and reverse GCGGGACATGACCTAAGAT. For each 
PCR, a mastermix was prepared on ice, containing per sample: 2 µL 
cDNA, 5 µL of 2× SensiFASTTM SYBR Green Reaction Mix (Bioline 
Inc., Taunton, MA, USA), and 0.4 µM of both reverse and forward 
primers. The PCRs were run on a QuantStudio 7 Flex real time PCR 
system thermocycler (Applied Biosystems, Foster City, CA, USA). 
The relative expression of genes was calculated using the compara-
tive threshold method, 2–ΔC1 [35], after efficiency correction of tar-
get and reference gene transcripts (HPRT) [36].
Serotonin Secretion Assay
The medium of monolayer and spheroids cultures was collect-
ed from each well. Ascorbic acid (0.1%) was added into all the 
samples that were used for the serotonin assay. The commercially 
available serotonin high sensitive ELISA (IBL international, Ham-
burg Germany) was used following the instructions of the manu-
facturer. Experiments were performed in quadruplicate and re-
peated twice.
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Western Blotting
To assess changes in the protein expression of SST2 and TPH-1, 
cells were washed and lysed in SDS-DTT buffer after 72 h of treat-
ment incubation. Proteins were separated by SDS-PAGE and 
transferred to nitrocellulose membranes (EMD Millipore, Billeri-
ca, MA, USA). Membranes were blocked with 5% non-fat dry milk 
in Tris-buffered saline with 0.05% Tween 20 and incubated over-
night at 4  ° C with primary antibodies (anti-β-tubulin: 2128S [Cell 
Signaling, Danvers, MA, USA]; anti-TPH-1: ab30574 [Abcam, 
Cambridge, UK]). Secondary horseradish peroxidase-conjugated 
anti-rabbit were purchased from Cell Signaling (Danvers, MA, 
USA). Proteins were developed by using ECL detection system 
(GE Healthcare, UK) with dyed molecular weight markers. A den-
sitometric analysis of the bands was carried out with ImageJ soft-
ware (National Institutes of Health, Bethesda, MD, USA).
Statistical Analysis
For the statistical analysis, the statistical software of GraphPad 
Prism version 5 (GraphPhad Software, San Diego, CA, USA) was 
used. Between-group comparisons were made by the Kruskal-
Wallis test. Differences were considered to be statistically signifi-
cant at p < 0.05. Results are expressed as mean ± SEM and percent-
ages unless otherwise specified. log transformation was used for 
calculating the IC50.
Results
Effects on Cell Proliferation and Serotonin Secretion
Telotristat strongly decreased serotonin secretion in a 
dose-dependent manner in BON-1 (Fig. 1a) and QGP-1 
cells (Fig. 1b) after 3 days of incubation. QGP-1 cells were 
more sensitive to telotristat (IC50: 1.3 × 10–9 M; 95% CI: 
7.3–2.4 × 10–9 M) than BON-1 cells (IC50: 3.3 × 10–8 M; 
95% CI: 1.8–6.2 × 10–8 M). The clinically relevant concen-
tration of telotristat (10–8 M) decreased serotonin secre-
tion by 40.1 ± 17.4% in BON-1 and by 72.5 ± 15.2% in 
QGP-1 cells (p < 0.001). Serotonin release was totally sup-
pressed in both cell lines after the incubation with the 
maximal evaluated dose (10–5 M) (p < 0.001). No statisti-
cally significant effect on cell growth (DNA content per 
well) was observed in cells incubated with telotristat for 3 
days in medium containing 0.1% BSA (Fig. 1) or 10% FCS 
(online suppl. Fig. 1). Additionally, cell metabolic activity 
was evaluated using an MTT assay. No statistically sig-
nificant effect on metabolic activity was observed in 
BON-1 or QGP-1 cells incubated with telotristat for 3 
days in medium containing 0.1% BSA (online suppl. 
Fig. 2A, B, respectively) or 10% FCS (online suppl. Fig. 2C, 
D respectively).
The combination treatment with telotristat and SSAs 
(PAS and OCT) had no statistically significant effect on 
cell growth in both cell lines (Fig.  2). In BON-1 cells, 
OCT 10–8, but not 10–9 M, decreased serotonin secretion 
by 26.7 ± 19.4% (p < 0.05). Remarkably, the effectiveness 
of the combination treatment of telotristat and OCT on 
serotonin release was slightly lower than telotristat alone 
(telotristat: 55.1 ± 13.1%, p < 0.001; telotristat + OCT 
10–8 M: 36.0 ± 29.4%, p < 0.01; telotristat + OCT 10–9 M: 
30.6 ± 25.5%, p < 0.01) in BON-1 cells (Fig. 2a). PAS 
(10–8 M) decreased serotonin secretion in BON-1 mono-
layer cultures more potently than OCT by 43.5 ± 6.6%, 
and its combination with telotristat had an additive ef-
fect (serotonin secretion reduction by 63.2 ± 8.9%; p < 
0.001) when compared to telotristat alone (44.1 ± 19.1; 
p < 0.001; Fig. 2b). PAS, at a concentration of 10–9 M, did 
not significantly reduce serotonin secretion in BON-1 
cells. 
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Fig. 1. Dose-dependent effect of telotristat 
on cell growth and serotonin secretion in 
monolayer PNET cells. a Effect of 3 days of 
treatment with telotristat on cell growth 
and serotonin secretion in BON-1 cells. b 
Effect of 3 days of treatment with telotristat 
on cell growth and serotonin secretion in 
QGP-1 cells. The interrupted line repre-
sents cell amount, the continuous line rep-
resents serotonin secretion. The gray verti-
cal dashed line represents the clinically rel-
evant plasma telotristat concentration. 
Values represent mean ± SEM and are 
shown as a percentage of untreated control 
cell amount (DNA content per well) or se-
rotonin concentration in the culture medi-
um. The mean of serotonin absolute values 
in BON-1 controls was 1,562 ± 130.7 pg/mL 
and in QGP-1 cells 84.96 ± 7.9 pg/mL.
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In QGP-1 cells, OCT 10–8 M and 10–9 M decreased se-
rotonin secretion by 21.1 ± 7.3% and –17.9 ± 21.0%, re-
spectively (p < 0.05). Combination treatment did not sig-
nificantly alter the effect of telotristat alone (Fig. 2c). Se-
rotonin secretion was not significantly affected by PAS 
(Fig. 2d).
Effects of Telotristat on the Autocrine Effect of 
Serotonin on Cell Proliferation in a 3D Spheroid 
Culture System 
In order to evaluate the potential autocrine/paracrine 
in vitro effect of serotonin on cell proliferation in BON-1 
and QGP-1 cells, a 3D spheroid culture system was used. 
The reduction in serotonin release induced by telotristat 
in BON-1 spheroids was similar to BON-1 monolayer 
cultures (Fig. 3a). QGP-1 spheroids were slightly less sen-
sitive to telotristat than the monolayer cultures, but the 
maximal concentration tested still fully abolished sero-
tonin secretion (10–5 M; p < 0.001; Fig. 3b). Despite the 
fact that serotonin secretion was totally suppressed after 
7 days of incubation with the maximal tested telotristat 
dose in both cell lines, no significant changes in spheroid 
growth (DNA content) were observed in BON-1 (Fig. 3a) 
or QGP-1 3D cultures (Fig. 3b). Serotonin levels also did 
not have an effect on the morphology of the spheroids. 
Representative images after 7 days of incubation without 
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Fig. 2. Effect of the combination therapy with telotristat and soma-
tostatin analogs on cell growth and serotonin secretion in mono-
layer PNET cells. a Combination treatment of telotristat (T) and 
octreotide (OCT) in BON-1 cells. b Combination treatment of T 
and pasireotide (PAS) in BON-1 cells. c Combination treatment T 
and OCT in QGP-1 cells. d Combination therapy of T and PAS in 
QGP-1 cells. Gray columns represent cell proliferation; white col-
umns represent serotonin secretion. For experiments on cell 
growth, DNA content per well was determined as a measure of cell 
number. Values represent mean ± SEM and are shown as a per-
centage of untreated control. * p < 0.05; ** p < 0.01; *** p < 0.001, 
compared to untreated controls. The mean of serotonin absolute 
values in BON-1 controls was 836.9 ± 67.3 pg/mL and in QGP-1 
cells 285.9 ± 25.4 pg/mL.
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or with telotristat are depicted in Figures 3c (BON-1 
spheroids) and d (QGP-1 spheroids). 
Effect of Telotristat on Somatostatin Receptor 
Expression
In order to rule out the possibility that telotristat influ-
ences SSTs expression, we evaluated the effect of telotri-
stat on SSTs subtype expression. Figure 4 shows that telo-
tristat (5 × 10–8 M for BON-1 and 10–9 M for QGP-1) had 
no significant effect on the expression of SSTs in mono-
layer cultures of BON-1 and QGP-1 cell lines (Fig. 4a, b, 
respectively). Similar results were observed in BON-1 and 
QGP-1 spheroids treated with telotristat (Fig. 5a, b, re-
spectively).
Effect of OCT and PAS on the Expression of TPH-1
In order to explore a putative mechanism of action of 
telotristat and the interaction with SSAs, we evaluated the 
effect of OCT and PAS on TPH-1 mRNA and protein ex-
pression. Figure 6 shows that OCT (10–8 M) or PAS (10–8 
M) did not have a statistically significant effect on the ex-
pression of TPH-1 in monolayer cultures of BON-1 and 
QGP-1 cell lines (Fig. 6a, b respectively). In addition, tel-
otristat (telotristat 5 × 10–8 M for BON-1 and 10–9 M for 
QGP-1), had no effect on TPH expression (Fig. 6a, b, right 
panels). To confirm these results, the expression of TPH-
1 was determined using Western blotting. OCT (10–8 M) 
or PAS (10–8 M) and telotristat (telotristat 5 × 10–8 M for 
BON-1 and 10–9 M for QGP-1) did not have a statistically 
significant effect on the protein expression of TPH-1 in 
BON-1 or QGP-1 cells (Fig. 7a, b, respectively).
Discussion
The aim of this study was to evaluate the in vitro effects 
of telotristat and its combination with SSAs on growth 
and serotonin secretion in a model of pancreatic NET 
cells. Some publications and clinical trials have reported 
the clinical and biochemical effects of telotristat in com-
bination with OCT in patients with carcinoid syndrome 
[8, 37, 38]. Recently, its use in patients with carcinoid syn-
drome and inadequately controlled diarrhea has been ap-
proved [16, 17]. Despite the clinical application of telotri-
stat, to the best of our knowledge only one published 
study has evaluated the effect of telotristat on synthesis of 
the serotonin precursor 5-hydroxytryptophan in a pan-
creatic NET cell line [39]. In the current study, we system-
atically evaluated the in vitro effects of telotristat on sero-
tonin secretion and cell growth in mono- and combina-
tion therapy with SSAs in two different pancreatic NET 
cell lines using 2D and 3D cell culture models.
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Telotristat did not affect cell proliferation in either 
monolayer or spheroid cultures, even when very high 
doses were tested. Moreover, no effects on the morphol-
ogy of 3D NET spheroids were observed. These results 
indicate that telotristat does not display any cytotoxicity, 
in concordance with clinical studies in which no serious 
adverse effects have been described. In addition, mild or 
moderate events were similar in patients treated with tel-
otristat and in those treated with placebo [8, 15, 37], sug-
gesting the relative safety of use of telotristat in NET pa-
tients.
Telotristat strongly decreased serotonin secretion in a 
dose-dependent manner in both cell lines similar to clin-
ical studies, in which the clinical and biochemical effects 
of telotristat were shown to be time- and dose-dependent 
[8, 15, 38]. Moreover, the concentration of telotristat that 
induced a 50% reduction of serotonin secretion by the 
NET cell lines (1.3 × 10–9 to 3.3 × 10–8 M) was in agree-
ment with the clinically relevant concentrations of the 
drug, i.e. 10–8 M [14]. Similarly, preclinical studies have 
reported decreased intestinal serotonin content after us-
ing small-molecule TPH-1 inhibitors [40, 41], and clini-
cal studies also reported statistically significant reduction 
from baseline u5-HIAA levels in patients with carcinoid 
syndrome who were already on a stable dose of SSAs [8, 
15, 38]. Preclinical experimental models of intestinal in-
flammation have also reported some beneficial roles of 
TPH-1 inhibitors including reduced colon and jejunum 
serotonin content, reduced expression of proinflamma-
tory genes, and reduced severity of chemical-induced 
colitis and enteric parasite-induced inflammation in mice 
[41]. Other beneficial effects of TPH-1 inhibitors include 
improvements in the mineral status, microarchitecture, 
and bone strength in animal models with chronic kidney 
disease [42]. 
Telotristat has been approved for the treatment of car-
cinoid syndrome (flushes and diarrhea) in combination 
with SSAs therapy in adults inadequately controlled by 
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Fig. 4. Effect of telotristat on mRNA expression profile of soma-
tostatin receptors in BON-1 and QGP-1 cell lines using monolay-
er culture systems. Relative mRNA expression normalized to 
HPRT in monolayer cultures of BON-1 (a) and QGP-1 (b) cell 
lines. The mRNA expression of BON-1 and QGP-1 was not statis-
tically significantly altered by telotristat at a concentration of 5 × 
10–8 and 10–9 M, respectively. Values represent mean ± SEM. ND, 
non-detectable.
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SSAs [17]. For this reason, we evaluated the effects of com-
bined treatment with telotristat and SSAs. Interestingly, 
despite the fact that the SST2 targeting SSA OCT slightly 
decreased serotonin secretion in BON-1 cells, its combina-
tion with telotristat was slightly less effective than the effect 
of telotristat alone. In QGP-1, no statistically significant 
effect of OCT on the inhibitory effect of telotristat on sero-
tonin secretion was observed. According to the available 
pharmaceutical information of telotristat ethyl, short-act-
ing OCT may decrease the systemic exposure to telotristat; 
to this aim, short-acting OCT should be administered 30 
min before telotristat [43]. In this context, the underlying 
mechanism, as well as its relevance in the clinical practice 
should be further explored, preferably in midgut NET cell 
lines and primary cultures of human midgut NETs. In 
BON-1, the multiligand SSA PAS inhibited serotonin se-
cretion more potently compared to OCT, which may be 
explained by the relative high expression of SST5 in this cell 
line [44, 45]. Moreover, this inhibitory effect was increased 
when PAS was combined with telotristat. Previous studies 
have evaluated the applicability of PAS in patients with car-
cinoid tumors resistant to other SSAs; unfortunately, the 
effects on symptom control are contradictory [46, 47]. 
Some studies have reported that in 33% of patients with 
carcinoid syndrome, PAS LAR is effective [46], but a ran-
domized phase III study of PAS LAR versus high-dose (40 
mg) OCT LAR for symptom control in patients with ad-
vanced GEP-NETs and carcinoid syndrome, whose dis-
ease-related symptoms were uncontrolled by first-genera-
tion SSAs at maximum approved doses, showed that PAS 
LAR was not superior to OCT LAR [47]. The increased 
incidence of hyperglycemia may limit its use as well [48]. 
It may therefore be important to evaluate the SSTs expres-
sion profile of the tumors using RT-qPCR or immunohis-
tochemistry [49–51] in order to consider alternative thera-
peutic options in functional NETs. 
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Fig. 5. Effect of telotristat on mRNA expression of somatostatin 
receptors in BON-1 and QGP-1 cell lines using a 3D spheroid cul-
ture system. Relative mRNA expression normalized to HPRT in 
spheroid cultures of BON-1 (a) and QGP-1 (b) cell lines. The 
mRNA expression of BON-1 and QGP-1 spheroids was not statis-
tically significantly altered by telotristat at a concentration of 5 × 
10–8 and 10–9 M, respectively. Values represent mean ± SEM. ND, 
non-detectable.
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Additionally, it has previously been described that the 
inhibition of serotonin production may modify the mo-
lecular expression of some genes [41]. Since the combina-
tion therapy with OCT slightly reduced the effect of telo-
tristat in BON-1 cells, we aimed to evaluate the effect of 
telotristat on mRNA expression of SSTs in monolayer 
and spheroids. However, no effect of telotristat on SSTs 
subtype expression was found. Serotonin biosynthesis is 
regulated by two isoforms of the enzyme TPH of which 
TPH-1 is localized predominantly in gastrointestinal en-
teroendocrine cells and TPH2 in the central nervous sys-
tem [52]. It is well known that telotristat is a highly spe-
cific and potent inhibitor of TPH [14]. In order to further 
explore the interaction between SSAs and telotristat, we 
evaluated the effect of SSA on TPH-1 expression. How-
ever, OCT and PAS did not alter the expression of TPH-1 
at mRNA or protein level. Therefore, the mechanism of 
interaction between OCT and telotristat remains to be 
elucidated. 
Interestingly, BON-1 cells secreted a higher amount of 
serotonin, compared to QGP-1. Moreover, QGP-1 cells 
were more sensitive to telotristat than BON-1. Neverthe-
less, mRNA expression of TPH-1 was comparable be-
tween BON-1 and QGP-1 cells, suggesting that other 
mechanisms should be responsible for the above differ-
ences in serotonin secretion between the two NET cell 
models. 
Finally, several autocrine effects of serotonin have been 
previously described, especially in relation to tumor pro-
gression [53]. Specifically, serotonin may promote the pro-
liferation of several tumor cell types [54–56], including 
lung non-small cell carcinoma, lung atypical carcinoid, as 
well as small intestine NET cells [57]. This autocrine effect 
may be reversed through the inhibition of serotonin syn-
thesis, release, and/or receptor activation [57]. To this aim, 
we evaluated the possible paracrine/autocrine effects of se-
rotonin on cell proliferation in a 3D spheroid NET model. 
This culture system seems to better reproduce tumor cell 
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telotristat on mRNA expression profile of 
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1 and QGP-1 cell lines in monolayer cul-
ture. Relative mRNA expression, normal-
ized to HPRT, in monolayer cultures of 
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mRNA expression of TPH-1 in BON-1 and 
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microenvironment, since it mimics the in vivo tumor cell-
cell signaling, growth kinetics, extracellular matrix deposi-
tion, nutrients-oxygen conditions, gene expression, drug 
resistance, cell heterogeneity, and cell-cell physical interac-
tions [58, 59]. Despite the above earlier observations, we 
did not observe changes in cell proliferation by treatment 
with telotristat, even when serotonin production was fully 
abolished. The discrepancy among the results may be ex-
plained by the difference in the origin of the used cell lines, 
which is also related to the considerable heterogeneity in 
NETs [60], also to the amount of serotonin secretion per 
cell line. Further studies including serotonin-producing 
NET cell lines of different origin (e.g., midgut), co-cultures 
with other cell lines (e.g., fibroblasts) and in vivo models 
should be performed. In this sense, the paracrine effect of 
serotonin on the tumor microenvironment may provide 
additional information for explaining NET pathogenesis 
and to identify putative additional targets. 
Other paracrine effects of serotonin include energy 
homeostasis and immune cell activation [61–64]. In this 
context, the inhibition of its production might have ad-
ditional clinical applications that still need to be eluci-
dated. Despite this, the TPH-1 inhibitor LP533401 did 
not have beneficial effects in an inflammatory model of 
periodontal disease [65], suggesting that, as in our study, 
the paracrine effect of this hormone still needs to be elu-
cidated. Despite the fact that telotristat etiprate is already 
commercially available for the control of diarrhea in SSA-
resistant carcinoid syndrome patients, it would be inter-
esting to find out whether different serotonin-producing 
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NET models exert a differential sensitivity to the drug. In 
addition, it is not known whether inhibition of paracrine- 
or autocrine-secreted serotonin by telotristat, without or 
with SSA, has an impact on NET proliferation. To address 
this issue, we used the 3D cell culture models of spheroids 
in this study. Future studies, including co-cultures with 
other cells, such as fibroblasts or immune cells, may show 
whether inhibition of serotonin production also has an 
impact on tumor-stromal interactions.
The lack of previously published articles on the direct in 
vitro effects of telotristat limits the depth of the discussion 
of our results. The in vitro effectiveness of telotristat can be 
evaluated in a small intestinal (SI) NET cell line model, or 
even primary cultures of midgut NET, which would repre-
sent the ideal tumor model, since carcinoid syndrome is 
more frequently associated with midgut carcinoids [6, 66]. 
Midgut NET cell lines are not widely available, and appro-
priate primary cultures are difficult to establish. A recent 
study showed that of seven established NET cell lines, only 
the SI-NET lines GOT-1 and P-STS and the PNET lines 
BON-1 and QGP-1 displayed a neuroendocrine pheno-
type and disease-characteristic mutations, while the other 
supposed SI-NET originating cell lines, e.g. KRJ-I, L-STS, 
and H-STS, did not and were identified as lymphoblastoid 
(KRJ-1) [23]. Unfortunately, the GOT-1 and P-STS cell 
lines are not available in our laboratory to confirm our 
findings in an SI-NET model. A previous report described 
the enterochromaffin origin of KRJ-I cells and suggested 
that due to the differences between this cell line and BON-
1 cells, both cell lines represent different models of entero-
chromaffin cell-derived NETs [67]. In this context, further 
studies evaluating the neuroendocrine characteristics of 
the available cell lines should be performed in order to im-
prove their selection and use.
To conclude, this study provides for the first time a 
comprehensive evaluation of the effect of telotristat in an 
in vitro NET model, confirming the potent inhibitory ef-
fect of clinically feasible concentrations of telotristat on 
serotonin release. We provided evidence for the absence 
of direct cell toxicity and showed additive inhibitory ef-
fects of telotristat and the multiligand SSA PAS on sero-
tonin secretion. 
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